OTC Stocks Popping

Reviewing OTC Gains  

We have been focusing a bit more on OTC stocks than we have in years in the middle of the global health crisis. When big board stocks get in trouble, many opportunistic short term traders will turn to the lower exchanges to seek out chances.

So that’s why our readers have seen an uptick in OTC mentions here in our daily newsletter offerings, and already we’ve seen multiple significant payoff opportunities. In our morning report from last Wednesday, we tagged NBDR, and the stock has produced a multi-bag run in just a short period. It has traded in a range from .0112-.0489, which represents a gain of 337%
_____

In addition to our premarket newsletters, any of our followers are welcome to participate in our daily traders chats on Skype (Contact request “stocksumo” to gain entry) to discover or share other opportunities throughout the course of each trading day. Here are a couple of coronavirus related chatroom plays from yesterday which fared very well:


Premier Biomedical, Inc. BIEI
Range: .0011-.0055 | Gain: 400%

American Biomedical Corp. ABMC
Range: .175-.43 | Gain: 146%


Fresh Options Ideas:
Direxion Daily Junior Gold Miners Index Bull 3X (ETF) JNUG Weekly $4-5 Calls 
Virgin Galactic Holdings, Inc. SPCE $13.50-16.50 Calls


Extended Watchlist:
BWMG, WINT, NEXCF, 

COVID Test FDA Green-Lit to Begin Shipments

Nova Bay Pharmceuticals, Inc. NBY

We are going to want to keep an eye out for NBY this week. The stock saw a surge last week, and is scheduled to report earnings on Thursday. The company recently launched a line of anti-microbial disinfecting wipes for the face and eyes. This has a unique synergy with the current health crisis, as one of the piomary ways to help slow the spread of COVID-19 is to limit the germ exchange which takes place when touching your face, and then touching objects around you.

It seems evident that consideration for how a stock related to the sweeping pandemic which experts warn could persist for as much as 18 months, is going to have to be built into virtually every idea we look at for our reports for the foreseeable future.


Aytu BioScience, Inc. AYTU

We’ve been tracking AYTU for a couple of weeks now, beginning with our report from the morning of the 10th. We want to rehash our interest in this coronavirus related play as the company announces the official FDA distribution green light for its rapid point-of-care diagnostic test.

We already witnessed a huge run by AYTU since we’ve been covering it, which was later mitigated  by a large public offering. However, we want to continue to stay hot on its trail in the wake of this morning’s news, which we’ll share below. The company expects the first shipment of 100,000 tests to be distributed presently, which is especially significant, considering that exceeds the total number of Amicans who have been tested so far, as the US lags behind almost every major country in that regard.

Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the company may begin distribution of its Coronavirus Disease 2019 (“COVID-2019”) IgG/IgM Rapid Test throughout the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care. (>>Read Full PR)


Target Corp. TGT

We also want to quickly update readers on a longer-term options options idea we recently submitted, the TGT 04/03 $98-90 Puts. It’s a wide range of contracts and toward the end of last week, the first of those began being pushed into the money as TGT fell.

The total ranges are as follows on the $98 and $97 Puts, and we are going to want to continue to monitor the entire range between now and next Friday, because this idea may just be getting warmed up. 

$98:
 2.51-5.79 (+131%)
$97:
3.50-5.59 (+60%)


Extended Watchlist:
TLRY, CGC, CRON, AMRX

TOMDF Run Continues

Todos Medical, Ltd. TOMDF

We have been tracking TOMDF since Tuesday morning in the premarket, when we included it in our extended watchlist. At the time, it was trading for as little as .0413 per share, and while it had a solid session that day, the gains hadn’t quite yet cracked the double-bag threshold.

Yesterday, after another really good performance, that mark was attained and then some. TOMDF has gone on to hit a new high of .17 for us, which works out to a big gain of 312%

The company’s rapid (2-10min) COVID-19 point-of-care test has been the primary reason for the stock’s huge moves. We will stay updated on the progress of the company getting the tests put into action, and will be interested to see if more upswings are on the horizon as a result.


Options Recaps

We signaled a range of options in the GILD chain in yesterday morning’s report. with the GILD Weekly $79-81 Calls. Thanks to a pretty good day for the markets, all things considered, we witnessed some very nice moves out of those targets.

Weekly $79-81 Calls
$79:
 3.44-8.00 (+133%)
$80: 2.68-7.42 (+177%)
$81: 2.49-6.05 (+143%)
_____

Fresh Ideas:
CRWD Weekly $47.50-50 Calls & 03/27 $52-53.50 Calls


Extended Watchlist:
TNXP, NBP, WTRH, BLPH, AMTX, PIXY, CEMI